Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor
Ohno, R.
Nihon Rinsho. Japanese Journal of Clinical Medicine 59(12): 2389-2394
2001
ISSN/ISBN: 0047-1852 PMID: 11766344 Document Number: 526883
STI571(imatinib) selectively inhibits the ABL-tyrosine kinase, the activity of which is activated by the formation of chimeric BCR/ABL. Phase I study in USA showed a remarkable effectiveness of STI571 in interferon-refractory chronic myelogenous leukemia with little adverse effects. STI571 will plausibly become the first choice drug prior to stem cell transplantation and interferon in the treatment of this leukemia.
Document emailed within 1 workday
Related Documents
Bhatia, R.; Munthe, H.A.; Verfaillie, C.M. 1998: Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors Leukemia 12(11): 1708-1717Wong, M.; Sade, S.; Gilbert, M.; Klieb, H.B.E. 2011: Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature Dermatology Online Journal 17(5): 4
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Ottmann, O.G.; Wassmann, B.; Hoelzer, D. 2002: Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec) Medizinische Klinik 97(Suppl 1): 16-21
Mahon, F.-X. 2019: When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clinical Advances in Hematology and Oncology: H&o 17(2): 101-103
Dou, X.L.; Wang, S.S.; Fang, J.L.; Yu, L.; Ren, X.; Huang, X.J.; Jiang, Q. 2018: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia Zhonghua Nei Ke Za Zhi 57(9): 649-655
Akagi, T.; Ono, H.; Shimotohno, K. 1996: Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells Oncogene 13(2): 399-405
Gelderblom, H.; Hogendoorn, P.C.; van der Graaf, W.T.; Verweij, J. 2003: Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor Nederlands Tijdschrift Voor Geneeskunde 147(42): 2051-2055
Haidary, A.M.; Azma, R.Z.; Ithnin, A.; Alauddin, H.; Tumian, N.R.; Tamil, A.M.; Razak, N.F.A.; Abu Amis, S.H.; Zin, N.M.; Shuib, S. 2019: FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy Malaysian Journal of Pathology 41(2): 149-160
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46
Cortes, J. 2012: Bosutinib in the treatment of chronic myelogenous leukemia Clinical Advances in Hematology and Oncology: H&o 10(11): 736-737
Kozai, T.; Shimokawa, H.; Fukumoto, Y.; Kobayashi, S.; Owada, M.K.; Kadokami, T.; Ito, A.; Kuwata, K.; Egashira, K.; Shiraishi, T.; Kanaide, H.; Takeshita, A. 1997: Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo Journal of Cardiovascular Pharmacology 29(4): 536-545
Gewirtz, A.M. 1994: Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides Bone Marrow Transplantation 14(Suppl 3): S57-S61
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Preisler, H.D.; Raza, A.; Higby, D.; Kirshner, J.; Woll, J.; Bennett, J.; Winton, L.; Weiner, R.; Richman, C.; Golomb, H. 1984: Treatment of myeloid blastic crisis of chronic myelogenous leukemia Cancer Treatment Reports 68(11): 1351-1355
Kantarjian, H.M.; Talpaz, M. 1994: Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia Seminars in Oncology 21(6 Suppl 14: 8-13
Sun, A.; Akin, R.S.; Cobos, E.; Smith, J. 2009: Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor Journal of Drugs in Dermatology: Jdd 8(4): 395-398
Hirano, M.; Miura, M.; Kakizawa, H.; Morita, A.; Uetani, T.; Ohno, R.; Kawashima, K.; Nishiwaki, H.; Yamada, K. 1972: Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally Cancer ChemoTherapy Reports 56(3): 335-338
Verstappen, M.C.H.M.; Mattijssen, V.; van der Reijden, B.A.; van der Heijden, A.J.P.; Wahab, P.J.; de Vries, R.A. 2006: A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib Nederlands Tijdschrift Voor Geneeskunde 150(21): 1188-1192
Mishra, N.C.; Sharma, M.; Sharma, A. 1999: Inhibitory effect of piceatannol, a protein tyrosine kinase inhibitor, on asexual maturation of Plasmodium falciparum Indian Journal of Experimental Biology 37(4): 418-420